UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE
14A-6(E)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to 240.14a-12
COMPETITIVE TECHNOLOGIES, INC.
(NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
(NAME OF PERSON(S) FILING PROXY STATEMENT, IF OTHER THAN THE REGISTRANT)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee
is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
*
*****
**-----**
**----- COMPETITIVE
****---- TECHNOLOGIES
**===== Unlocking the Potential of Innovation (R)
**=====**
*****
* (R)
Dear Fellow Shareholder:
You are cordially invited to attend the Competitive Technologies, Inc.
Annual Meeting of Shareholders on Monday, April 19, 2010, at 11:00 a.m. ET. The
meeting will be held at the Hilton Stamford Hotel & Executive Meeting Center, 1
First Stamford Place, Stamford, Connecticut, phone (203) 967-2222.
The matters to be acted upon are described in the accompanying notice of
Annual Meeting and proxy statement. At the meeting, we will also report on our
company's successful commercialization of our Calmare pain therapy treatment
medical device, including FDA clearance and CE approval, the many distribution
agreements we have in place covering nearly 50% of the world's population, and
especially the progress we have made in sales and marketing of the device. I
look forward to discussing our exciting business opportunities and responding to
any questions you may have.
This year we are pleased to again apply the U.S. Securities and Exchange
Commission rule that allows companies to furnish proxy materials to stockholders
primarily over the Internet. We believe this method should expedite receipt of
your proxy materials, lower costs of our Annual Meeting and help conserve
natural resources. We encourage you to vote via the Internet by following the
links to the Proxy Statement and Annual Report, which are both available at
www.proxyvote.com.
YOUR VOTE IS VERY IMPORTANT. I URGE YOU TO VOTE "FOR" ALL PROPOSALS.
Please review your proxy materials carefully and vote today.
On behalf of the Board of Directors, I express our appreciation for your
continued support toward the profitable growth of CTT. We look forward to
seeing you at the Annual Meeting.
Very truly yours,
\s\ John B. Nano
----------------
John B. Nano
Chairman, President and CEO
Fairfield, Connecticut
February 25, 2010
COMPETITIVE TECHNOLOGIES, INC.
777 COMMERCE DRIVE
FAIRFIELD, CONNECTICUT 06825
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
The Annual Meeting of Shareholders of Competitive Technologies, Inc. will
be held at the Hilton Stamford Hotel & Executive Meeting Center, 1 First
Stamford Place, Stamford, CT, on Monday, April 19, 2010, at 11:00 a.m. ET. The
purposes of the meeting are:
1. To elect five Directors to serve until the next Annual Meeting of
Shareholders or until their respective successors have been elected
and qualified, and
2. To ratify the selection of MHM Mahoney Cohen, CPAs as our
independent registered public accounting firm for the fiscal year
ending July 31, 2010, and
3. To transact such other business as may properly come before the
meeting and any adjournment or postponement thereof.
Our board of directors recommends a vote FOR Items 1 and 2. Only
shareholders of record at the close of business on February 22, 2010, will be
entitled to notice of and to vote at the Annual Meeting of Shareholders and any
adjournment or postponement thereof. The board has successfully commercialized
the pain therapy medical device with FDA clearance and CE approval, and
completed sales and distribution agreements that have the potential to be the
most profitable technology in our 40-year history. Now we need your vote.
WE URGE YOU TO VOTE YOUR SHARES PROMPTLY. PLEASE REFER TO THE SPECIFIC
VOTING INSTRUCTIONS.
By Order of the Board of Directors,
\s\ John B. Nano
JOHN B. NANO
Chairman, President and CEO
Fairfield, Connecticut
February 25, 2010
*
*****
**-----**
**----- COMPETITIVE
****---- TECHNOLOGIES
**===== Unlocking the Potential
**=====** of Innovation (R)
*****
* (R)
INTERNET AVAILABILITY OF PROXY MATERIALS
We are furnishing proxy materials to our shareholders primarily via the
Internet under rules adopted by the U.S. Securities and Exchange Commission
(SEC), instead of mailing printed copies of those materials to each shareholder.
Our shareholders are receiving a Notice of Internet Availability of Proxy
Materials containing instructions on how to access our proxy materials,
including our Proxy Statement and our Annual Report. The Notice of Internet
Availability of Proxy Materials also instructs you on how to access your proxy
card to vote via the Internet or telephone.
This process is designed to expedite shareholders' receipt of proxy
materials, lower the cost of the Annual Meeting and help conserve natural
resources. If you would prefer to continue to receive printed proxy materials,
please follow the instructions included in the Notice of Internet Availability
of Proxy Materials.
HOW TO VOTE
If your shares are held by a broker, bank or other stockholder of record
exercising fiduciary powers which holds securities of record in nominee name or
otherwise, typically referred to as being held in "street name", you may receive
a separate voting instruction form, or you may need to contact your broker, bank
or other stockholder of record to determine whether you will be able to vote
electronically via the Internet or telephone.
Because of a change in NYSE rules, we note that, unlike at previous annual
meetings, your broker will NOT be able to vote your shares with respect to the
election of directors if you have not provided directions to your broker. We
strongly encourage you to submit your proxy card and exercise your right to vote
as a shareholder.
If you are a stockholder with shares registered in your name, you may vote
by either of the following methods:
- VOTE VIA THE INTERNET, by going to the web address
www.proxyvote.com and following the instructions for internet voting.
- VOTE BY TELEPHONE, by dialing 1-800-690-6903 and following the
instructions for telephone voting.
PLEASE NOTE THAT IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR
OTHER STOCKHOLDER OF RECORD AND YOU WISH TO VOTE AT THE ANNUAL MEETING, YOU WILL
NOT BE PERMITTED TO VOTE IN PERSON AT THE ANNUAL MEETING UNLESS YOU FIRST OBTAIN
A LEGAL PROXY ISSUED IN YOUR NAME FROM THE RECORD HOLDER.
COMPETITIVE TECHNOLOGIES, INC.
-------------------
PROXY STATEMENT
FOR ANNUAL MEETING OF SHAREHOLDERS
-------------------
The Board of Directors is furnishing shareholders this proxy statement to
solicit proxies to be voted at the Annual Meeting of Shareholders of Competitive
Technologies, Inc. (CTT), a Delaware corporation. The meeting will be held on
Monday, April 19, 2010, at 11:00 a.m. ET at the Hilton Stamford Hotel &
Executive Meeting Center, 1 First Stamford Place, Stamford, CT.
VOTING RIGHTS AND SOLICITATION OF PROXIES
Record Date. The record date for the Annual Meeting is the close of
business on February 22, 2010. Only shareholders of record on that date will be
entitled to notice of, and to vote at, the Annual Meeting.
Quorum. The Company's bylaws provide that the holders of a majority of the
Common Stock issued and outstanding and entitled to vote generally in the
election of directors, present in person or represented by proxy, shall
constitute a quorum for the transaction of business at the Annual Meeting.
Abstentions and broker non-votes will be counted as present for the purpose of
determining the presence of a quorum.
Voting Your Proxy. Exercise your vote in accordance with the method of
your choice, via the Internet or by telephone. The proxy will be voted as you
direct. In the event no directions are specified, your shares will be voted (1)
FOR the election of the nominees named below as directors; (2) FOR the
ratification of the selection of MHM Mahoney Cohen, CPAs; and at the discretion
of the designated proxy holders as to other matters that may properly come
before the Annual Meeting.
IF YOU ARE A SHAREHOLDER OF RECORD, holding a stock certificate registered
in your name on the books of our transfer agent, American Stock Transfer & Trust
Company, as of the close of business on February 22, 2010, and attend the
meeting, you may vote in person at the meeting on proxies available at the
meeting for that purpose, or revoke a previously submitted proxy and complete a
new proxy.
IF YOUR SHARES ARE HELD IN A STOCK BROKERAGE ACCOUNT WITH YOU AS A
BENEFICIAL OWNER, because of a change in NYSE rules, unlike at previous annual
meetings, your broker will NOT be able to vote your shares with respect to the
election of directors if you have not provided directions to your broker. We
strongly encourage you to exercise your right to vote as a shareholder. In order
to do so,
- you must return your voting instructions to your broker or
nominee, the holder of record, OR
- you must vote your shares through your broker or nominee via the
internet or by phone, OR
- if you wish to vote in person at the meeting, you must obtain
from the record holder and bring to the meeting a proxy SIGNED BY THE
RECORD HOLDER identifying you as the beneficial owner of the shares
and giving you the right to vote the shares at the meeting. (You may
NOT use the voting instruction form provided by your broker or nominee
to vote in person at the meeting.)
1
Revoking Your Proxy. You may revoke your proxy at any time before the
voting closes by notifying us; no formal procedure is required. Votes are
tabulated by an independent agent, and reported at the Annual Meeting.
We intend to make available to our shareholders this proxy statement,
including the Notice of Annual Meeting of Shareholders, on or about February 25,
2010.
Holders of common stock and of preferred stock at the close of business on
the record date of February 22, 2010, are entitled to vote at the meeting:
Common stock: 10,911,029 shares outstanding, one vote per share
Preferred stock: 2,427 shares outstanding, one vote per share
If you abstain from voting, your shares will be counted as shares present
and entitled to vote in determining the presence of a quorum for the meeting,
but will not be voted in determining approval of any matter submitted to
shareholders for a vote. An abstention will have the same effect as a negative
vote on a matter submitted to shareholders for a vote. If a broker indicates
that it does not have discretionary authority to vote on a particular matter,
broker non-votes, those shares will be counted as shares present in determining
the presence of a quorum for the meeting but will not be considered present or
entitled to vote with respect to that particular matter.
2
1. ELECTION OF DIRECTORS
At the Annual Meeting, shareholders will elect a Board of five directors by
a plurality of the votes cast. Our Board of Directors proposes the five
nominees named below. We recommend voting FOR the five named nominees for the
Company to continue the successful commercialization of our pain therapy medical
device.
All nominees named below served as directors since the last Annual Meeting
of Shareholders. There are no family relationships among our executive officers
and directors. Based on its review of the relationships between its existing
directors, as director nominees, and CTT, the Board of Directors has
affirmatively determined that if these nominees are elected, a majority of our
directors will be independent under the rules of the NYSE Amex and CTT's
Corporate Governance Principles.
If any nominee is unable to serve, we solicit discretionary authority to
vote to elect another person unless we reduce the size of the Board. Each
director will serve until the next Annual Meeting of Shareholders, or until his
or her successor has been elected and qualified, or until his or her earlier
resignation or removal. We believe that all nominees will be available for
election as a director for the prescribed term.
The following table sets forth information regarding each nominee for
director according to the information furnished to us by each such nominee:
POSITIONS CURRENTLY COMMITTEE DIRECTOR OF
NAME AGE HELD WITH CTT MEMBERSHIPS CTT SINCE
------------------------ --- ------------------- ----------- -------------
Joel M. Evans, M.D. 49 Director A, N February 2007
Richard D. Hornidge, Jr. 64 Director A, C* February 2007
Rustin Howard 53 Director C, N* October 2007
Chairman of the
Board of Directors,
President and Chief
John B. Nano 65 Executive Officer -- February 2007
William L. Reali 67 Director A*, C, N February 2007
A - Audit Committee
C - Compensation and Stock Option Committee
N - Nominating and Corporate Governance Committee
* - Committee Chair
JOEL M. EVANS, M.D. Dr. Evans founded The Center for Women's Health in
Stamford, Connecticut in June 1996 and since then has been its Director. From
November 1996 to present, Dr. Evans has been a lecturer and senior faculty
member of The Center for Mind Body Medicine in Washington, D.C. Dr. Evans has
been featured in magazines as well as interviewed on television and radio shows
across the country. Dr. Evans is an Assistant Clinical Professor at the Albert
Einstein College of Medicine in New York City and helped create a clinical study
at Columbia University Medical Center for use of the herb, black cohosh, in
breast cancer. From November 2005 to present, Dr. Evans has been a member of
the Scientific Advisory Board for Metagenics Incorporated, a nutritional
supplement manufacturer. Dr. Evans brings key medical experience to the
Company.
Dr. Evans completed his undergraduate and medical studies at the Sophie
Davis School of Biomedical Education of the City College of New York and the Mt.
Sinai School of Medicine. He fulfilled his residency at the Albert Einstein
College of Medicine.
RICHARD D. HORNIDGE, JR. Mr. Hornidge has been a tennis professional since
February 2005, currently at the Newburyport Racquet Club in Newburyport,
Massachusetts, and earlier at Willows Racquet Club in North Andover,
Massachusetts.
3
Prior to that he was an independent consultant. From June 1984 through
June 1989, Mr. Hornidge was President of Travis Associates, an employment
agency. Mr. Hornidge was a program coordinator for Raytheon from 1973 through
1984, where he was involved in the Patriot Missile test equipment program.
He has won numerous tennis tournaments, and was a member of two USTA teams
that competed nationally. He was ranked #1 in New England in paddle-tennis for
most of his 20-year career, in the top 16 on a national level, and was
three-time National Champion in various senior divisions.
Mr. Hornidge received a BA from Boston University after serving in the U.S.
Navy.
RUSTIN HOWARD. Mr. Howard is principal of Whitesand Investments LLC, an angel
investment organization.
In 1990, he founded and served as CEO and Chairman of Phyton, Inc., a world
leader in the use of proprietary plant cell fermentation technology, including
the production of paclitaxel, the active ingredient of Bristol-Myers Squibb's
multi-billion dollar anticancer drug, Taxol . Phyton was sold to DFB
Pharmaceuticals, Inc. in 2003.
Additionally, Mr. Howard is the Chairman of DeepGulf, Inc., and a co-owner
and officer of Silver Bullet Technology. DeepGulf builds underwater pipelines
and associated facilities in deep and ultra-deep offshore oil and gas production
fields. Silver Bullet Technology, where he has been primarily responsible for
corporate and financial oversight as well as strategic planning, manufactures
and sells software for the banking and payment processing industry. Previously,
he served as president and CEO of BioWorks Inc., a biotechnology company he
founded to develop, produce, and sell products that replace chemical pesticides.
He earned his MBA from Cornell University's Johnson Graduate School of
Management, where he focused his studies on Entrepreneurship, and managing
innovation and technology.
JOHN B. NANO. Mr. Nano is President and Chief Executive Officer of Competitive
Technologies, Inc. and Chairman of the Board of Directors. In January 2006 Mr.
Nano became President and Chief Executive Officer of Articulated Technologies,
LLC. a company involved in creating and commercializing patented light emitting
diode technologies for global solid-state lighting applications. He is
currently a member of their Board of Directors. Mr. Nano served as President
and CEO, and a member of the Board of CTT from June 2002 through June 2005. He
has a broad background in domestic and international operating experience with
technology-based companies focusing on life sciences, physical sciences, digital
technology and electronics. Prior to joining CTT in 2002, Mr. Nano held various
executive leadership positions in operations, strategic planning, business
development, M&A and finance, including at Stonehenge Network Holdings, N.V. as
a Principal, at ConAgra Trade Group, a subsidiary of ConAgra, Inc., as Executive
VP and Chief Financial Officer; at Sunkyong America, a subsidiary of the
Sunkyong Group, a Korean conglomerate, as Executive VP and Chief Financial
Officer, and as President of an Internet Startup Division of Sunkyong America.
Mr. Nano is a graduate of MIT's Sloan School Executive Program, holds an
MBA in Finance from Northeastern University, and a BS in Chemical Engineering
from Worcester Polytechnic Institute.
WILLIAM L. REALI. Mr. Reali is a Certified Public Accountant with the firm of
Reali, Giampetro and Scott in Canfield, Ohio. The firm provides auditing and
other related accounting and tax services to a diverse group of business
clients. Over the past five years, Mr. Reali's primary responsibility with the
firm has been business consulting, working with large and small national and
multinational clients. He has worked with distressed companies, assisting them
with cost reduction, turn-around programs and re-organization.
4
Serving as Chairman of various community associations, Mr. Reali donates a
great deal of time to local organizations.
Mr. Reali received his BA from Youngstown State University.
VOTE REQUIRED
The affirmative vote of a plurality of the shares our common stock
represented in person or by proxy at the Annual Meeting is necessary for the
election of the individuals named above. There is no cumulative voting in
elections of directors. Unless otherwise specified, proxies will be voted in
favor of the five nominees described above.
RECOMMENDATION
Our Board of Directors recommends that shareholders vote FOR the election
of each of the individuals named above.
CORPORATE GOVERNANCE
CTT's Corporate Governance Principles, Corporate Code of Conduct, the
Committee Charters for the Audit Committee and the Nominating and Corporate
Governance Committee of the Board of Directors, the unofficial restated
Certificate of Incorporation and the By-Laws are all available on our website at
www.competitivetech.net/investors/governance.html.
-------------------------------------------------
BOARD MEETINGS AND COMMITTEES
The Board has three committees, as follows:
COMPENSATION AND STOCK NOMINATING AND CORPORATE
AUDIT COMMITTEE OPTION COMMITTEE GOVERNANCE COMMITTEE
------------------------ ------------------------- ------------------------
William L. Reali, Richard D. Hornidge, Jr., Rustin Howard,
Chairman Chairman Chairman
Joel M. Evans, M.D. Rustin Howard Joel M. Evans, M.D.
Richard D. Hornidge, Jr. William L. Reali William L. Reali
During the fiscal year ended July 31, 2009, the board of directors met six
times, the audit committee held four meetings and the compensation committee
held two meetings. The nominating and corporate governance committee held three
meetings during fiscal year ended July 31, 2009. In 2009, all directors
attended at least 75% of all meetings of the board of directors and the
committees on which they served after becoming a member of the board or
committee. We, and the board, expect all directors to attend the next Annual
Meeting barring unforeseen circumstances or irresolvable conflicts.
Audit Committee
The function of the Audit Committee is to assist the Board in fulfilling
its responsibility to the shareholders relating to our corporate accounting
matters, financial reporting practices, and the quality and integrity of our
financial reports. The Audit Committee's purpose is to assist the Board with
overseeing:
- the reliability and integrity of our financial statements,
accounting policies, internal controls and disclosure practices;
- our compliance with legal and regulatory requirements, including
our disclosure controls and procedures;
5
- our independent auditor's qualifications, engagement,
compensation, and independence;
- the performance of our independent auditor; and
- the production of an annual report of the Audit Committee for
inclusion in our annual proxy statement.
The Audit Committee is to be composed of not less than three of our
independent directors. The Board has determined that each member of the Audit
Committee is an independent director in accordance with the applicable rules of
the NYSE Amex and any other applicable legal or regulatory requirements. It has
also determined that each member is financially literate and has identified Mr.
Reali, who is a certified public accountant, as an audit committee financial
expert as defined by the Securities and Exchange Commission.
Compensation and Stock Option Committee
The purpose of the Compensation Committee is to:
- review and approve corporate goals and objectives relevant to CEO
compensation, evaluate the CEO's performance in light of those goals
and objectives, and determine and approve the CEO's compensation level
based on this evaluation;
- review and approve the compensation of our other officers based
on recommendations from the CEO;
- review, approve and make recommendations to the Board with
respect to incentive compensation plans or programs, or other
equity-based plans or programs, including but not limited to our
Annual Incentive Plan, and our 401(k) Plan; and
- produce an annual report of the Compensation Committee on
executive compensation for inclusion in our annual proxy statement.
The Compensation Committee is to be composed of not less than three of our
independent directors. The Board has determined that each member of the
Compensation Committee is an independent director in accordance with the
applicable rules of the NYSE Amex and any other applicable legal or regulatory
requirements.
Nominating and Corporate Governance Committee
The purpose of the Nominating Committee is to:
- identify individuals qualified to become members of the Board,
consistent with criteria approved by the Board;
- recommend to the Board, candidates for all directorships to be
filled by the Board or our shareholders;
- in consultation with the Chairman of the Board, recommend to the
Board, members of the Board to be appointed to committees of the Board
and the chairpersons thereof, including filling any vacancies;
- develop and recommend to the Board a set of corporate governance
principles applicable to us;
- oversee, evaluate and monitor the Board and its individual
members, and our corporate governance principles and procedures; and
- fulfill such other duties and responsibilities as may be set
forth in its charter or assigned by the Board from time to time.
The Nominating Committee is to be composed of not less than three of our
independent directors. The Board has determined that each member of the
Nominating Committee is an independent director in
6
accordance with the applicable rules of the NYSE Amex and any other applicable
legal or regulatory requirements.
The Nominating Committee will consider nominees recommended by shareholders
but have not designated any special procedures shareholders need to follow to
submit those recommendations. The Nominating Committee has not designated any
such procedures because as discussed below under the heading "Shareholder
Communications to the Board," shareholders are free to send written
communications directly to the Board, committees of the Board, and/or individual
directors, at our corporate address in care of our Secretary.
SHAREHOLDER COMMUNICATIONS TO THE BOARD
Shareholders may send communications in writing to the Board, committees of
the Board, and/or to individual directors, at our corporate address in care of
our Secretary. Written communications addressed to the Board are reviewed by
the Chairman of the Board for appropriate handling. Written communications
addressed to an individual Board member are forwarded to that person directly.
BENEFICIAL OWNERSHIP OF SHARES
The following information indicates the beneficial ownership of our Common
Stock by each director nominee, and by each person known to us to be the
beneficial owner of more than 5% of our outstanding Common Stock. The indicated
owners, with sole voting and investment power, furnished such information to us
as of February 22, 2010, except as otherwise indicated in the footnotes.
NAMES OF BENEFICIAL OWNERS AMOUNT
(AND ADDRESS, IF OWNERSHIP IS BENEFICIALLY
MORE THAN 5%) OWNED (1) PERCENT (%)
Director nominees
-----------------
Joel M. Evans, M.D. 56,300 (2) *
Richard D. Hornidge, Jr. 127,635 (2) 1.2
Rustin Howard 73,500 (2) *
John B. Nano 432,301 (2) 4.0
William L. Reali 57,500 (2) *
Director nominees total: 747,236 6.8
------------------------
Five percent beneficial owner
-----------------------------
Prescott Group Capital Management LLC
1924 S Utica Suite F 1120
Tulsa, OK 74104 771,440 7.1
* Less than 1%
(1) Designated person or group has sole voting and investment power.
(2) Persons listed below have the right to acquire the listed number of
shares upon exercise of stock options:
NAME RIGHT TO ACQUIRE
------------------------------------------- ----------------
Joel M. Evans, M.D. 40,000
Richard D. Hornidge, Jr. 40,000
Rustin Howard 40,000
John B. Nano 400,000
William L. Reali 40,000
Directors and Executive Officers as a Group 560,000
7
On February 22, 2010, the stock transfer records maintained by us with
respect to our Preferred Stock showed that the largest holder of Preferred Stock
owned 500 shares. No directors own Preferred Stock.
DIRECTOR COMPENSATION
The following table summarizes the total compensation awarded to, earned by
or paid by us for services rendered during fiscal year 2009 to the non-employee
Board of Director members:
OPTION OTHER EQUITY
FEES EARNED OR AWARDS COMPENSATION
NAME PAID IN CASH(3) (1) (2) TOTAL
--------------------------- --------------- -------- -------------- -------
Joel M. Evans, M.D. $ 16, 00 $ 6,470 $ 2,513 $24,983
Richard D. Hornidge, Jr. 15,500 6,470 2,513 24,483
Rustin Howard 16,000 6,470 - 24,983
William L. Reali 21,500 6,470 2,513 30,483
Former Board Member:
Ralph S. Torello (4) 13,500 6,470 2,513 22,483
1) Each director serving on January 2, 2009 received a stock option for
10,000 shares of common stock at $1.005 per share under the 2000 Directors Stock
Option Plan. We estimated the fair value of stock awards at $0.647 per share
using the Black-Scholes option valuation model with expected life of 5 years,
risk free interest rate of 1.72%, volatility of 79.04% and dividend yield of 0.
See Item 14 in Notes to Consolidated Financial Statements in Part II, Item 8.
2) Each director serving on January 2, 2009 received 2,500 shares of stock
under the 1996 Directors Stock Participation Plan. The fair market value of the
stock was $1.005 per share.
3) This amount includes unpaid fees of $13,833, $14,833, $14,333, and
$16,833 for Dr. Evans, Mr. Hornidge, Mr. Howard, and Mr. Reali respectively.
4) Mr. Torello served as Director in fiscal 2008, and did not stand for
re-election as a Director in 2009. The size of the Board was reduced from six
members to five members. The compensation shown is for the period Mr. Torello
served as a director during fiscal 2009 prior to the election of directors held
at the Annual Meeting on April 17, 2009.
OUTSTANDING EQUITY AWARDS AT JULY 31, 2008
NUMBER OF SECURITIES OPTION OPTION
UNDERLYING UNEXERCISED EXERCISE EXPIRATION
NAME OPTIONS (1) PRICE DATE
------------------------- ----------------------- --------- ----------
Joel M. Evans, M.D. 10,000 $ 2.58 8/2/17
10,000 1.51 1/2/18
10,000 1.005 1/2/19
Richard D. Hornidge, Jr. 10,000 2.58 8/2/17
10,000 1.51 1/2/18
10,000 1.005 1/2/19
Rustin Howard 10,000 2.29 10/5/17
10,000 1.51 1/2/18
10,000 1.005 1/2/19
William L. Reali 10,000 2.58 8/2/17
10,000 1.51 1/2/18
10,000 1.005 1/2/19
Former Board Member:
Ralph S. Torello (2) 10,000 2.58 8/2/17
8
(1) Each stock option was granted pursuant to our 2000 Directors
Stock Option Plan. The shares were vested immediately on issuance.
(2) Mr. Torello served as Director in fiscal 2008, and did not stand
for re-election as a Director in 2009. The size of the Board was
reduced from six members to five members.
Each of our non-employee directors is paid an annual cash retainer of
$10,000, paid quarterly in arrears, for their services to the Company. In
addition, directors are issued shares of common stock pursuant to our 1996
Directors Stock Participation Plan, as amended, and are granted stock options to
purchase common stock pursuant to our 2000 Directors Stock Option Plan, both as
described below. In addition, effective in fiscal year 2005, the Chairman of
the Board, if a non-employee, and the Chairman of the Audit Committee are paid
annual stipends for the additional responsibilities and time commitments
required of them. Mr. Nano, as an employee of the Company, has not been paid
any compensation for serving as Chairman of the Board. Mr. Reali has served as
Chairman of the Audit Committee since February 2, 2007 and he received a $6,000
stipend in 2009.
Each non-employee director is also paid $1,000 for each Board meeting
attended and $500 for each committee meeting attended. All directors are
reimbursed for out-of-pocket expenses incurred to attend Board and committee
meetings.
Pursuant to our 1996 Directors Stock Participation Plan, as amended, on the
first business day of January, each non-employee director who has been elected
by the stockholders and has served at least one full year as a director is
issued a number of shares of common stock equal to the lesser of $15,000 divided
by the per share fair market value of such stock on the issuance date, or 2,500
shares. If a non-employee director were to leave the Board after serving at
least one full year, but prior to the January issuance date, we will issue
shares of common stock to the director on a pro-rata basis up to the termination
date. Common stock may not be issued pursuant to this plan after January 3,
2011.
Pursuant to our 2000 Directors Stock Option Plan, non-employee directors
are granted 10,000 fully vested, non-qualified stock options to purchase our
common stock on the date the individual is first elected as a director, whether
by the stockholders or by the Board, and is granted 10,000 options on the first
business day of January thereafter, provided the individual is still a director.
The stock options granted are at an exercise price not less than 100% of the
fair market value of the common stock at the grant date and have a term of ten
years from date of grant. If an individual's directorship terminates because of
death or permanent disability, the stock options may be exercised within one
year after termination. If the termination is for any other reason, the stock
options may be exercised within 180 days after termination. However, the Board
has the discretion to amend previously granted stock options to provide that
such stock options may continue to be exercisable for specified additional
periods following termination. In no event may a stock option be exercised
after the expiration of its ten-year term. Stock options could not be granted
under this plan after the first business day of January 2010.
BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act")
requires our directors and officers, and persons who own more than five percent
of the Common Stock to file reports of ownership and changes in ownership with
the Securities and Exchange Commission ("SEC") and the NYSE Amex. SEC
regulations require reporting persons to furnish us with copies of all Section
16(a) forms they file.
Based solely on a review of copies of such reports received or written
representations from certain reporting persons, we believe all reporting persons
complied with all applicable reporting requirements.
9
CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS, DIRECTOR INDEPENDENCE
Our Board of Directors determined that when a director's services are
outside the normal duties of a director, we compensate the director at the rate
of $1,000 per day, plus expenses, which is the same amount we pay a director for
attending a one-day Board meeting. We classify these amounts as consulting
expenses, included in personnel and other direct expenses relating to revenues.
We incurred a charge of $54,000 and $70,500 in 2009 and 2008, respectively,
for consulting services provided by a relative of our President and CEO.
CTT's Board Directors, Evans, Hornidge, Howard, and Reali are considered to
be independent directors as defined by the NYSE Amex. Director Nano is not
considered an independent director, as he is an employee of the Company.
REPORT OF THE COMPENSATION AND STOCK OPTION COMMITTEE
This report of the Compensation and Stock Option Committee (the
"Committee") shall not be deemed incorporated by reference by any general
statement incorporating the Proxy Statement by reference into any filing under
the Securities Act of 1933 or the Securities Exchange Act of 1934 (the "Acts"),
except to the extent that CTT specifically incorporates this information by
reference, and shall not otherwise be deemed filed under such Acts.
CTT's compensation program consists of base salary, bonus, stock options,
other incentive awards and other benefits, which the Committee generally reviews
annually. The Committee's overall philosophy is to align compensation with our
business strategy and to support achievement of our long-term goals. In order to
attract and retain competent executives, we believe it is essential to maintain
an executive compensation program that provides overall compensation competitive
with that paid to executives with comparable qualifications and experience.
The Board of Directors is reviewing all compensation plans to assure
effectiveness and fiduciary responsibility.
COMPENSATION AND STOCK OPTION COMMITTEE REPORT:
We have reviewed and discussed with management certain Executive
Compensation and Compensation Discussion and Analysis provisions to be included
in the Company's Annual Report on Form 10-K, filed pursuant to the Securities
Exchange Act of 1934, as amended (the "Annual Report"). Based on the reviews and
discussions referred to above, we recommend to the Board of Directors that the
Executive Compensation and Compensation Discussion and Analysis provisions
referred to above be included in the Company's Annual Report.
Submitted by the Compensation and Stock Option Committee of the Board of
Directors
Richard D. Hornidge, Jr. (Chairman)
Rustin Howard William L. Reali
REPORT OF THE AUDIT COMMITTEE
The Audit Committee reviewed and discussed with management our audited
financial statements as of and for the year ended July 31, 2009, as well as our
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the year ended
July 31, 2009, before those reports were filed.
10
The Audit Committee discussed with our independent accountants, MHM Mahoney
Cohen, CPAs the matters required to be discussed by Statement on Auditing
Standards No. 61, "Communication with Audit Committees," as issued, modified or
supplemented.
The Audit Committee received the written disclosures from MHM Mahoney Cohen
required by Independence Standards Board Standard No. 1, "Independence
Discussions with Audit Committees," as issued, modified or supplemented. The
Audit Committee discussed with MHM Mahoney Cohen their independence from
management and from CTT.
The Audit Committee discussed with MHM Mahoney Cohen the overall scope,
plans and budget for its audit. In addition, the Audit Committee meets with MHM
Mahoney Cohen regularly, with or without management present, to discuss the
results of MHM Mahoney Cohen's examination, evaluation of CTT's internal
controls, and the overall quality of CTT's financial reporting.
Based on the reviews and discussions referred to above, the Audit Committee
recommended to the Board of Directors that the audited financial statements as
of and for the year ended July 31, 2009, be included in our Annual Report on
Form 10-K for the year ended July 31, 2009.
AUDIT COMMITTEE:
William L. Reali (Chairman)
Joel M. Evans, M.D. Richard D. Hornidge, Jr.
EXECUTIVE OFFICER
On April 17, 2009, at the Annual Meeting of the Shareholders of the
Company, shareholders supported the installation of the Board. The Board met and
re-elected John B. Nano to his current executive officer position with the
company.
NAME AGE POSITION WITH CTT
--------------------- --- ---------------------------------------------------
Current Executive Officer:
Chairman of the Board of Directors,
President and Chief Executive Officer,
John B. Nano 65 Interim Chief Financial Officer
EXECUTIVE COMPENSATION
COMPENSATION DISCUSSION AND ANALYSIS
We have a standing compensation committee on our Board. Our President
makes recommendations to the committee as to employee benefit programs and
officer and employee compensation.
Annual Base Salary. The base salary for John B. Nano was set in a three-year
employment agreement effective February 2, 2007. That agreement automatically
renewed for a one-year period effective February 2, 2010, per the terms of the
agreement.
Annual Cash Bonus. In addition to the competitive annual base salary, we intend
to reward executive officers each year for the achievement of specific goals,
which may be financial, operational or technological. We consider objectively
measurable goals, such as obtaining new investment capital, negotiating valuable
contracts and achieving research and regulatory milestones, and more subjective
goals, such as quality of management performance and consistency of effort.
CTT's objectives include operating, strategic and financial goals the board
considers critical to CTT's overall goal of building
11
shareholder value. Our recommendations for cash bonuses also take into account
CTT's liquidity and capital resources in any given year.
The following table summarizes the total compensation awarded to, earned by
or paid by us for services rendered by the 3 highest paid employees that served
during the fiscal years 2009 and 2008.
NAME AND ALL OTHER
PRINCIPAL POSITION YEAR SALARY BONUS OPTION AWARDS COMPENSATION TOTAL
------------------------------ ---- ----------- ------ -------------- -------------- --------
Current Executive Officers:
John B. Nano (1) 2009 $350,000(5) $ - $ 179,333 $ 39,889(3) $569,222
Chairman of the Board
of Directors, President and 2008 363,702 - 153,749 29,534(2) 546,985
Chief Executive Officer,
Interim Chief Financial
Officer
Aris D. Despo
Executive Vice President -
2009 209,999(6) - 9,730 7,584(4) 227,313
Business Development 2008 219,650 - 8,975 - 228,625
John P. Rafferty
Vice President
and Controller 2009 115,001 - 4,865 4,151(4) 124,017
Girish Nallur
Executive Vice President -
Chief Scientific Officer 2008 145,385 - 8,975 - 154,360
(1) Mr. Nano's salary does not include any additional compensation
for serving as Chairman of the Board.
(2) Payment of auto lease.
(3) Includes $30,461 for payment of auto lease, $1,167 for auto
repairs, and discretionary contribution of 5,511 shares of CTT common
stock (valued at $8,267) contributed to the Company's 401(k) plan.
(4) Represents discretionary contribution to the Company's 401(k)
plan of 5,056 shares of CTT common stock for Mr. Despo and 2,767
shares for Mr. Rafferty.
(5) Beginning in January 2009, Mr. Nano began deferring one half his
salary until the company is in a stronger cash flow position. This
amount includes deferred wages of $94,231.
(6) Beginning in January 2009, Mr. Despo began deferring a portion of
his salary until the company is in a stronger cash flow position. This
amount includes deferred wages of $32,308.
GRANTS OF PLAN BASED AWARDS
The following table shows equity awards granted to named executive officers
during fiscal 2009 and 2008. Equity awards identified in the table below are
also reported in the Outstanding Equity Awards at 2009 Year End Table.
OPTION
AWARDS: CLOSING GRANT DATE
NUMBER OF MARKET FAIR VALUE
SECURITIES EXERCISE PRICE ON OF STOCK
GRANT UNDERLYING PRICE GRANT OPTION GRANTS
NAME DATE OPTIONS (1) ($/SHARE) DATE ($) ($)(2)
------------- ------------- ----------- --------- --------- --------------
Aris Despo 9/28/07(3) 30,000 2.25 2.25 42,960
Girish Nallur 9/28/07(5)(3) 30,000 2.25 2.25 42,960
12
(1) Granted pursuant to our 1997 Employees Stock Option Plan.
(2) These amounts reflect the fair value as of the option grant date
as determined by SFAS 123(R) for accounting purposes. For a
description of the assumptions used to determine the grant date fair
value, see Note 14 of Notes to Consolidated Financial Statements in
Part II, Item 8.
(3) These stock options vest 25% on the first anniversary of the
grant and 25% annually thereafter.
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
NUMBER OF NUMBER OF
SECURITIES SECURITIES
UNDERLYING UNDERLYING
UNEXERCISED UNEXERCISED OPTION
OPTIONS OPTIONS OPTION EXPIRATION
NAME EXERCISABLE(1) UNEXERCISABLE(1) PRICE DATE
----------------- -------------- ---------------- ------- ----------
John Nano 300,000 100,000(2) $ 2.52 02/02/17
Aris D. Despo 7,500 22,500(3) 2.25 9/28/17
John P. Rafferty 3,750 11,250(3) 2.25 9/28/17
(1) Option awards under our 1997 Employees Stock Option Plan.
(2) Options vest on February 2, 2010.
(3) Vesting schedule: 33% each on September 28, 2009, 2010, and 2011,
respectively.
OPTION EXERCISES DURING FISCAL YEAR 2009
There were no options exercised during fiscal year 2009.
EMPLOYMENT, SEVERANCE AND CHANGE OF CONTROL ARRANGEMENTS
John B. Nano signed an employment agreement with the Company on February 2,
2007. The agreement provides for his employment for a period of three years
from the effective date, with automatic annual renewal thereafter, effective 180
days prior to each anniversary. The agreement states that the Company employs
Mr. Nano as its President and Chief Executive Officer, and that he reports to
the Company's Board of Directors. The agreement also states that Mr. Nano was
appointed to the Board as its Chairman, without additional compensation. The
agreement established his starting annual base salary at $350,000, subject to
reviews and increases at the sole discretion of the Board.
Mr. Nano's responsibilities and duties are appropriate to the position of
Chief Executive Officer the Company, including, without limitation, developing
and implementing an overall strategic plan and annual business plans, raising
new capital, and supervising day-to-day operations. The agreement entitles Mr.
Nano to receive a yearly bonus of up to 50% of his base compensation, based upon
the Company's performance and his performance of objectives during that time
period as determined by the Compensation Committee of the Board. Mr. Nano's
agreement provides for reimbursement of business related expenses, a leased car,
and participation in employee benefit programs and plans.
The Company granted Mr. Nano ten year options ("Plan Options") for the
purchase of an aggregate of 400,000 shares of the Company's common stock at the
mean average of the high and low share price on the effective date of the
agreement. The Plan Options vest 25% immediately upon employment, and an
additional 25% on each successive one-year anniversary of the date of employment
13
If Mr. Nano resigns his employment for good reason, as defined in the
employment agreement, or the Company terminates his employment without cause, he
will be entitled to receive all accrued but unpaid salary and benefits through
the date of termination plus severance benefits. In the event Mr. Nano resigns
from the Company without good reason, or if the Company terminates his
employment with cause, the Company has no liability to him except to pay his
base compensation and any accrued benefits through his last day worked, and he
will not be entitled to receive severance or other benefits.
In the event of Mr. Nano's death, or if he is unable to fulfill his obligations
to the Company due to illness, injury, physical or mental incapacity or other
disability, for any 120 days within any 12 month period, all obligations under
the agreement are terminated; except that: the Company will pay his base
compensation and accrued benefits to him or to his estate, and any unvested Plan
Options granted under this agreement will become fully vested and immediately
exercisable for a period of one year by him or his estate. In the event of his
death, any post-retirement benefits shall be paid to Executive's estate. In the
event of his disability, he will be reimbursed for one-time premium
post-retirement health coverage not to exceed $120,000.
If the Company terminates Mr. Nano's employment without cause in conjunction
with a Change in Control, he will be entitled to receive all accrued but unpaid
salary and benefits through the date of termination plus the Change in Control
benefit.
The agreement's severance benefit granted to Mr. Nano provides for no less than
twelve months continuation of his base compensation, his employment benefits,
vesting of Options granted, and reimbursement for post retirement health
coverage.
The agreement's Changes in Control benefit granted to Mr. Nano provides for
continuation of compensation in effect to be paid for a period of either twice
the amount of the severance benefit period, or the remainder of his employment
term, whichever is longer; continuation of his employment benefits and
reimbursement for post-retirement health care benefits; and full and immediate
vesting of any unvested but outstanding Options.
The following table summarizes the value of benefits payable to Mr. Nano
pursuant to the arrangements described above. Calculations are based on the
termination, resignation or change of control taking place as of July 31, 2009,
the last day of our most recent fiscal year.
SUMMARY OF POTENTIAL PAYMENTS AT JULY 31, 2009 FOR JOHN B. NANO EMPLOYMENT
CONTRACT
POST
BENEFITS OPTIONS RETIREMENT
SEVERANCE SUMMARY VESTING HEALTHCARE TOTAL
($) ($) ($) ($) ($)
----------- ---------- ----------- ---------- ---------
Resignation - - - - -
Termination
- cause - - - - -
Death or disability - - 102,733 (5) 120,000 222,733
Resignation
- good reason 350,000 (1) 56,226 (3) 102,733 (5) 120,000 629,959
Termination
- w/o cause 350,000 (1) 57,226 (3) 102,733 (5) 120,000 629,959
Change of control 700,000 (2) 114,451 (4) 102,733 (5) 120,000 1,037,184
(1) Reflects minimum severance benefit of one year's base salary.
(2) Reflects minimum change in control benefit of two years base salary.
(3) Reflects continued benefits of auto, medical, dental, vision and
life insurance plan coverage for the severance benefit period (12
months).
(4) Reflects continued benefits of auto, medical, dental, vision and
life insurance plan coverage for the change in control benefit period
(24 months).
(5) Reflects accelerated vesting of the unamortized cost of the
options, as if the officer continued employment for the remaining term
of the agreement.
14
OTHER ARRANGEMENTS
401(K) RETIREMENT SAVINGS PLAN
We have an employee defined contribution plan qualified under section
401(k) of the Internal Revenue Code for all our employees who have attained the
age of 21 and meet certain service requirements. The Plan has been in effect
since January 1, 1997. Participation in the Plan is voluntary. Employees may
defer compensation up to a specific dollar amount determined by the Internal
Revenue Service for each calendar year. We do not make matching contributions,
and employees are not allowed to invest in our stock under the Plan.
Our directors may authorize a discretionary contribution to the Plan,
allocated according to the provisions of the Plan, and payable in shares of our
common stock valued as of the date the shares are contributed. Our directors
authorized and we expensed $50,000 in fiscal 2009 for such discretionary
contributions. We contributed the 33,333 related shares of our common stock to
the Plan in fiscal 2009.
ANNUAL INCENTIVE PLAN
The Competitive Technologies, Inc. Annual Incentive Plan was approved by
our Board on November 22, 2005, replacing a prior plan. The Compensation
Committee administers the Incentive Plan. The Compensation Committee may
suspend or amend the Incentive Plan at any time from time to time, and the Board
may terminate the Incentive Plan.
The Incentive Plan provides for eligible employees to earn an annual bonus
incentive in cash. The targeted annual bonus incentive award is a percentage of
the participant's salary earned during the plan year, as defined in the
Incentive Plan, and is comprised of two parts, 50% of which is dependent upon
attainment of financial performance metrics that serve as our company wide goals
and objectives and are set at the beginning of the year, the Company Component;
and 50% of which is dependent upon the individual's performance compared to each
individual's pre-established goals and objectives, the Individual Component. If
our financial performance is less than 70% of its goal, there will be no award
for the Company Component. If our financial performance is more than 120% of
its goal, then the Company Component award will increase to 125% of the award,
and may, under certain conditions, as defined, increase up to a maximum of 200%
of the award. If a participant meets his or her individual goals, we may pay
the Individual Component regardless of whether the Company Component is met.
We did not incur any expense for annual bonus incentive awards to employees
other than the Named Executive Officers for the years ended July 31, 2009, and
2008.
1997 EMPLOYEES' STOCK OPTION PLAN
The 1997 Employees' Stock Option Plan provided for the granting of stock
options to purchase our Common Stock. Stock options granted under the Stock
Option Plan may have been incentive stock options pursuant to Section 422 of the
Internal Revenue Code or non-statutory stock options. Stock options granted
under the Stock Option Plan must have been granted at not less than 100% of the
fair market value on the date of grant. The Compensation Committee determines
the vesting period for the stock options. Stock options expire upon termination
of the grantee's employment, or ten years after the grant date. In certain
instances stock options which are vested or become vested upon the occurrence of
an event or events specified by the Compensation Committee, may continue to be
exercisable through up to ten years after the grant date, irrespective of the
termination of the optionee's employment with us. No options were allowed to be
granted pursuant to this plan after September 30, 2007.
15
NUMBER OF
SECURITIES
REMAINING
NUMBER OF WEIGHTED- AVAILABLE
SECURITIES AVERAGE FOR FUTURE
TO BE ISSUED EXERCISE ISSUANCE
UPON EXERCISE PRICE OF (EXCLUDING
OF OUTSTAND- OUTSTANDING OPTIONS
PLAN CATEGORY ING OPTIONS OPTIONS OUTSTANDING)
---------------------------- ------------- ------------ ------------
Equity compensation plans
approved by security holders 806,325 $ 3.35 182,000-
2. ELECTION OF INDEPENDENT PUBLIC ACCOUNTANTS
Mahoney Cohen & Company, CPA, P.C. ("Mahoney Cohen") have been the
independent registered public accountants for the company. Pursuant to an asset
purchase agreement, our former independent public accounting firm, Mahoney Cohen
& Company, CPA, P.C. was acquired by the New York practice of Mayer Hoffman
McCann P.C ("MHM"), and the shareholders of Mahoney Cohen became shareholders of
MHM. Following its acquisition of Mahoney Cohen, MHM changed its name to MHM
Mahoney Cohen, CPAs ("MHM Mahoney Cohen"), effective December 31, 2008.
Fees Billed by Principal Accountants - The following table presents fees
for professional services rendered by Mahoney Cohen and MHM Mahoney Cohen for
the years ended July 31, 2009 and 2008:
2009 2009 2009 2008
-------- -------- ---------- --------
Mahoney MHM Full Year Mahoney
Cohen Mahoney Total Cohen
Cohen
-------- -------- ---------- --------
Audit fees $ 90,304 $ 30,000 $ 120,304 $142,299
Tax fees - 1,483 1,483 4,000
Audit related fees (1) 5,211 2,000 7,211 8,400
-------- -------- ---------- --------
TOTAL $ 95,515 $ 33,483 $ 128,998 $154,699
======== ======== ========== ========
(1) Fees for S-1 and S-8 review.
AUDIT COMMITTEE PRE-APPROVAL OF SERVICES OF PRINCIPAL ACCOUNTANTS
The Audit Committee has the sole authority and responsibility to select,
evaluate, determine the compensation of, and, where appropriate, replace the
independent auditor. After determining that providing the non-audit services is
compatible with maintaining the auditor's independence, the Audit Committee
pre-approves all audits and permitted non-audit services to be performed by the
independent auditor, except for de minimus amounts. If it is not practical for
the Audit Committee to meet to approve fees for permitted non-audit services,
the Audit Committee has authorized its chairman, currently Mr. Reali, to approve
them and to review such pre-approvals with the Audit Committee at its next
meeting.
RATIFICATION OF SELECTION OF INDEPENDENT PUBLIC ACCOUNTANTS
The persons named in the enclosed proxy will vote to ratify the selection
of MHM Mahoney Cohen as independent public accountants for the year ending July
31, 2010, unless otherwise directed by the shareholders. Shareholder
ratification of MHM Mahoney Cohen as the Company's independent public
accountants is not required by the Company's bylaw or otherwise. However, the
Company is submitting selection of MHM Mahoney Cohen to the shareholders for
ratification as a matter of good corporate practice. If the shareholders do not
ratify the selection of MHM Mahoney Cohen as the Company's independent public
accountants, the Audit Committee will reconsider the selection of such
independen
16
public accountants. If the selection is ratified, the Audit Committee may, in
its discretion, direct the appointment of different independent public
accountants at any time during the year if it determines that such a change
would be in the best interest of the Company and its shareholders.
VOTE REQUIRED
The affirmative vote of a majority of the shares of Common Stock present or
represented by proxy at the Annual Meeting is necessary for the ratification of
MHM Mahoney Cohen as independent public accountants for the fiscal year ended
July 31, 2010.
RECOMMENDATION
Our Board of Directors recommends that shareholders vote FOR the
ratification of MHM Mahoney Cohen as independent public accountants for the
fiscal year ended July 31, 2010.
PROPOSALS OF SHAREHOLDERS
Shareholders who wish to present proposals under SEC Rule 14a-8 to be
included in our Proxy Statement and form of proxy in connection with the April
2011 Annual Meeting of Shareholders, must submit those proposals so that we
receive them no later than 120 days before the proxy availability date of our
Proxy Statement in connection with that meeting. If we meet this year's proxy
availability date of February 25, 2010, we must receive such proposals for next
year's Annual Meeting no later than October 28, 2010.
Shareholders who wish to present matters outside the processes of SEC Rule
14a-8 to be included in our Proxy Statement and form of proxy in connection with
the April 2011 Annual Meeting of Shareholders, must submit notice of those
matters so that we receive them no later than 45 days before the proxy
availability date of our Proxy Statement in connection that meeting. If we meet
this year's expected availability date of February 25, 2010, we must receive
notice of such matters for next year's Annual Meeting no later than January 10,
2011. Notice received after January 10, 2011 will be untimely and subject to
the discretionary authority described in the last sentence of this Proxy
Statement.
17
GENERAL
We will pay the cost of soliciting proxies, including preparation,
assembly, printing and mailing of the Notice of Internet Availability of Proxy
Materials, and any additional information furnished to shareholders.
Arrangements will be made to furnish solicitation materials to brokerage houses,
custodians, nominees and other fiduciaries, holding in their names shares of
common stock beneficially owned by others to forward to such beneficial owners.
We will reimburse these third-parties for reasonable out-of-pocket expenses.
Solicitation of proxies by mail may be supplemented by telephone, telegram,
electronic transmission or personal solicitation by our directors, officers or
other regular employees of the Company. No additional compensation will be paid
to directors, officers or other regular employees for such services. We have
retained Morrow & Co., LLC. located at 470 West Avenue, Stamford, CT 06902, for
an estimated fee of $5,000, plus out of pocket expenses, to assist in
distributing proxy materials and soliciting proxies.
Copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, any amendments to those reports and any other
reports filed with or furnished to the SEC also are available on or through our
website at www.competitivetech.net as soon as reasonably practicable after they
-----------------------
are filed with or furnished to the SEC.
Upon written request, we will provide without charge (except for exhibits)
to any shareholder of record or beneficial owner of our securities, a copy of
our Annual Report on Form 10-K filed with the SEC for the year ended July 31,
2009, including the financial statements and schedules thereto. Exhibits to
said report will be provided upon payment of fees limited to our reasonable
expenses in furnishing such exhibits. Written requests should be addressed to:
Secretary, Competitive Technologies, Inc., 777 Commerce Drive, Fairfield,
Connecticut, 06825.
Some brokers and other nominee record holders may be participating in the
practice of "householding" corporate communications to shareholders, such as
proxy statements and annual reports. This means that only one copy of this
Proxy Statement, including the Notice of Internet Availability of Proxy
Materials, may have been sent to multiple shareholders in your household. We
promptly will deliver a separate copy of this Proxy Statement to you if you call
or write us at the following address or phone number: Secretary, Competitive
Technologies, Inc., 777 Commerce Drive, Fairfield, Connecticut, 06825,
telephone: (203) 368-6044. If in the future you want to receive separate
copies of our corporate communications to shareholders, such as the Notice of
Internet Availability of Proxy Materials, proxy statements and annual reports,
or if you are receiving multiple copies and would like to receive only one copy
for your household, you should contact your broker or other nominee record
holders, or you may contact us at the above address and phone number.
The Board of Directors is not aware of any matter that is to be presented
for action at the meeting other than the matters set forth herein. Should any
other matters requiring a vote of the shareholders arise, the proxies in the
enclosed form confer upon the person or persons entitled to vote the shares
represented by such proxies' discretionary authority to vote the same in respect
of any such other matters in accordance with their best judgment in the interest
of CTT.
By Order of the Board of Directors,
JOHN B. NANO
Chairman, President and CEO
Dated: February 25, 2010
18
*
*****
**-----**
**----- COMPETITIVE
****---- TECHNOLOGIES
**===== Unlocking the Potential of Innovation (R)
**=====**
*****
* (R)
19